March 11, 2026 8:08am

Usually steam rolls C&GT sector’s share pricing as economists anticipate that CPI rose +2.4% on a year-over-year basis

Oil prices moved higher early on today, despite a report that there might be a historic release of emergency reserves from the International Energy Agency.

Financing News: CRISPR Therapeutics AG (CRSP) priced $550 M of its convertible senior notes due 2031 in a private offering. CRSP also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50 million aggregate principal amount of the notes. The sale of the notes is expected to close on 3/16/26. The offering was upsized from the previously announced offering of $350 million aggregate principal number of notes.

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t! 

Say/write less, mean more …

Tuesday’s RMi Closing Bell: The share pricing tug-a-war, literally … https://www.regmedinvestors.com/articles/14343  

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Updated:  Wednesday: The pre-open Dow futures are DOWN -0.26% or (-124 points), the S&P futures are DOWN -0.13% or (-9 points) and the Nasdaq futures are DOWN -0.03% or (-6.75 points)

  • U.S. stock futures are inching/fluctuating lower
  • European markets opened lower as traders monitor Iran war development
  • Asia Pacific markets closed mostly higher

Economic Data: Consumer Price Index (CPI and its cores plus year-over-year), Fed Vice Chair for Supervision Michelle Bowman speaks about bank supervision and at 2 p.m. Monthly U.S. federal budget

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Tuesday: The Dow closed DOWN -34.29 points or -0.07%, the S&P closed DOWN -14.49 points or -0.21% while the Nasdaq closed UP +1.158 points or +0.01%
  • Monday: The Dow closed UP +239.25 points or +0.50%, the S&P closed UP +55.97 points or +0.83% while the Nasdaq closed UP +308.267 points or +1.38%
  • Last week: The S&P 500 was down -2%, the Dow -0.3% and the Nasdaq was down -1.2%.
  • The previous week: The Dow finished down -1.3% for the week, the NASDAQ declined 0.9%, and the S&P 500 slipped -2%. 
  • February: The Dow inclined +0.2%, the Nasdaq dived -3.3% and S&P 500 declined -1%.

 

Q1/26 – Q1 – March – 2 positive and 4 negative closes

  • February – 1 market holiday, 11 positive and 8 negative closes
  • January – 2 holiday, 2 neutral, 9 negative and 9 positive closes 

Q4/25:

  • December, 1 holiday, 8 positive and 12 negative closes
  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Multiple earnings coming as sector releases Qs and FY25 …

................  Holding

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

Worries about the knock-on effects from the Iran war have dominated markets this week, spurring oil market volatility that has reverberated through stocks. Crude prices rose on reports three vessels came under fire in the Strait of Hormuz on today’s morning, as the Iran war continues to menace shipping. <Yahoo Finance>

  • Meanwhile, the IEA has proposed a record release of reserves to ease the supply crunch and put the brakes on a roaring oil rally that …had lifted prices toward $120 per barrel.

Beyond geopolitics, investors are preparing for the first of two highly anticipated inflation readings due this week.

  • February’s Consumer Price Index report is set for release at 8:30 a.m. ET, followed by January’s Personal Consumption Expenditures index on Friday.
  •  

Economists surveyed by … Bloomberg … anticipate a 0.3% monthly rise in consumer prices and annual inflation remaining flat at 2.4%. On a "core" basis, excluding volatile energy and food categories, economists expect a monthly increase of 0.2% and a yearly boost of 2.5%.

  • The data is expected to provide insight into inflation trends and the broader health of the US economy, particularly as recent indicators suggest the labor market may be losing some momentum.
  • It won't, however, capture the effects of the oil price surge this month.

 

“I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • Are the dice … hot, as they say it is STILL a “crap shoot”        
  • Keep that in mind...  losers quickly turn lower and  winners turn into losers. 

 

Investors has been looking for further insight into sector earnings; the Q4 and FY25 earnings reporting cycle. So far …

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Mesoblast (MESO), Vericel (VCEL) and BioLife Solutions (BLFS)
  • Monday – 3/2 uniQure NV (QURE)
  • Thursday - 3/5 Regenxbio (RNX)
  • Tuesday – 3/10 – BioNTech, SE (BNTX)

 

Welcome to my world of defining the “grey’ in our universe!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

March – 2nd week

  • 3/10 - Tuesday closed positive with 21 incliners, 16 decliners and 3 flats
  • 3/9 - Monday closed positive with 35 incliners, 2 decliners and 3 flats

March – 1st week

  • 3/6 - Friday closed negative with 14 incliners, 24 decliners and 2 flats
  • 3/5 – Thursday closed negative with 7 incliners, 32 decliners and 1 flat
  • 3 /4 – Wednesday closed positive with 32 incliners, 6 decliners and 2 flats
  • 3/3 - Tuesday closed negative with 2 incliners, 36 decliners and 2 flats
  • 3/2 - Monday closed negative with 15 incliners, 23 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.